Key facts
- Genomenon’s last known valuation is $68.0M.
- It has raised $36.8M across 4 recorded rounds; the latest was Early Stage VC ($5.5M) in May 2024.
- Notable investors include Michigan Rise, Invest Detroit Ventures, Innovation Partnerships, Beringea, Spring Mountain Capital — 25 tracked in total.
- Genomenon has filed 4 Form Ds with the SEC since 2015, most recently May 2024 ($5.5M sold to 30 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Genomenon
Funding rounds
4 roundsAbout Genomenon
Developer of genome interpretation software designed to improve cancer diagnosis and treatment. The company's software offers a set of diagnostic and discovery tools to identify disease-causing genomic variants and assists in treating cancer and other heritable diseases, enabling physicians to improve patient outcomes.
- Sector
- Healthcare
- HQ
- Ann Arbor, MI, United States
- Founded
- 2014
- Employees
- 150
- Website
- genomenon.com/
- Ownership
- Privately Held (backing)
Genomenon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genomenon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genomenon in its N-PORT filings yet. We sweep new filings monthly.